文献速递关节外科

移动加压泵深静脉血栓预防:对药物预防说不

Mobile pump deep vein thrombosis prophylaxis: just say no to drugs.
PubMed 文献 · Bone Joint J · 2017-01-01

本文回顾移动加压装置(MCD)在全关节置换术(TJA)后静脉血栓栓塞症(VTE)预防中的文献,并讨论本机构数据。既往研究表明华法林和Xa因子抑制剂等更激进抗凝方案增加伤口并发症、再手术和再入院率,而MCD预防的症状性VTE率为0.92%,与更激进抗凝方案相当。基于个人深静脉血栓史、VTE家族史、活动性癌症或高凝状态的术前风险分层方案可使超过70%患者避免激进预防性抗凝,同时保持低症状性VTE发生率。

要点

  • MCD预防的症状性VTE率为0.92%,与更激进抗凝方案相当。
  • 华法林和Xa因子抑制剂等方案增加伤口并发症、再手术和再入院率。
  • 术前风险分层可使超过70%患者避免激进预防性抗凝,症状性VTE发生率低。

核心结论

  • 需要对阿司匹林在VTE预防中的作用以及MCD作为独立预防治疗的效果进行进一步研究。

研究设计与样本

  • 本文为文献综述,回顾MCD用于全关节置换术后VTE预防的当前文献,并讨论本机构数据。

主要发现

  • 研究显示使用MCD预防的症状性VTE率为0.92%,与更激进抗凝方案所见率相当。
  • 既往研究显示华法林和Xa因子抑制剂等更激进抗凝方案增加术后伤口并发症、再手术和再入院率。
  • 一项既往前瞻性研究发现,基于个人深静脉血栓史、VTE家族史、活动性癌症或高凝状态的术前风险分层方案可使超过70%患者避免激进预防性抗凝,同时保持低症状性VTE发生率。

临床怎么用

  • 术前风险分层方案基于个人深静脉血栓史、VTE家族史、活动性癌症或高凝状态,可使超过70%患者避免激进预防性抗凝。

局限性

  • 需要对阿司匹林在VTE预防中的作用以及MCD作为独立预防治疗的效果进行进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The purpose of this article was to review the current literature pertaining to the use of mobile compression devices (MCDs) for venous thromboembolism (VTE) following total joint arthroplasty (TJA), and to discuss the results of data from our institution. PATIENTS AND METHODS: Previous studies have illustrated higher rates of post-operative wound complications, re-operation and re-admission with the use of more aggressive anticoagulation regimens, such as warfarin and factor Xa inhibitors. This highlights the importance of the safety, as well as efficacy, of the chemoprophylactic regimen. RESULTS: Studies have shown a symptomatic VTE rate of 0.92% with use of MCDs for prophylaxis, which is comparable with rates seen with more aggressive anticoagulation protocols. A prior prospective study found that use of a pre-operative risk stratification protocol based on personal history of deep vein thrombosis, family history of VTE, active cancer, or a hypercoaguable state allowed for the avoidance of aggressive prophylactic anticoagulation in over 70% of patients while maintaining a low incidence of symptomatic VTE. CONCLUSION: Further investigation is needed into the role of aspirin in VTE prophylaxis as well as the efficacy of MCDs as stand-alone prophylactic treatment. Cite this article: Bone Joint J 2017;99-B(1 Supple A):8-13.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Haynes J, Barrack RL, Nam D, et al. Mobile pump deep vein thrombosis prophylaxis: just say no to drugs. Bone Joint J. 2017. PMID: 28042112. doi:10.1302/0301-620X.99B1.BJJ-2016-0165.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。